Evommune, INC

Evommune, Inc. has dosed the first patient in its Phase 2b clinical trial for EVO756, an MRGPRX2 inhibitor, for migraine prophylaxis, with top-line data expected in 2027.

Evommune, Inc. announced that its EVO756 Phase 2b trial for chronic spontaneous urticaria did not meet its primary endpoint, leading to the discontinuation of development for this indication.

Evommune, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Evommune announced its first quarter 2026 financial results, highlighting progress in its EVO756 and EVO301 clinical programs with key data readouts expected throughout 2026.

Evommune, Inc. hosted a webcast on April 13, 2026, discussing the migraine treatment landscape and the role of MRGPRX2 inhibition, with a focus on their drug candidate EVO756.

Evommune, Inc. announced positive Phase 2a data for EVO301 in atopic dermatitis, reported full-year 2025 financial results, and closed a $125 million private placement extending its cash runway through 2028.

Evommune, a clinical-stage biotechnology company, reported positive Phase 2a results for EVO301 in atopic dermatitis and detailed its financial position following a November 2025 IPO and a February 2026 private placement.

Evommune, Inc. Chief Financial Officer Kyle Carver reported a transaction involving the purchase of 1,000 shares of common stock.

Director Arthur Kirsch acquired 10,000 shares of Evommune, Inc. common stock for $13.30 per share on July 7, 2026.

Evommune, Inc. reports Janice Suzann Drew's transactions of common stock and employee stock options under a pre-arranged trading plan.

Evommune, Inc. reports insider transactions by Chief Scientific Officer Jeegar Pravinkumar Patel, involving stock options and common stock under a Rule 10b5-1 trading plan.

Evommune, Inc. President & CEO Luis C. Pena reported the sale of 7,438 shares of common stock for $22.71 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Benjamin F. McGraw III was granted 15,673 stock options in Evommune, Inc. as part of standard equity compensation.

Evommune, Inc. has issued a proxy statement announcing its 2026 Annual Meeting of Stockholders, scheduled for June 2, 2026, to elect directors and ratify auditor appointments.

Evommune, Inc. has filed a registration statement for the resale of up to 4,494,279 shares of common stock by existing stockholders.

LSP 7 Cooperatieve U.A. increased its beneficial ownership in Evommune, Inc. to 14.7% by purchasing 358,680 shares for nearly $10 million in a recent private placement.

Point72 Asset Management, L.P., along with affiliated entities and Steven A. Cohen, has reported beneficial ownership of 5.3% of Evommune, Inc.'s common stock as of July 15, 2026.

Nan Fung Group Holdings Limited and its affiliated entities have disclosed beneficial ownership of up to 10.9% of Evommune, Inc.'s common stock.